.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Novartis
Harvard Business School
US Army
Dow
Teva
QuintilesIMS
Mallinckrodt

Generated: September 20, 2017

DrugPatentWatch Database Preview

ADALAT Drug Profile

« Back to Dashboard

Which patents cover Adalat, and when can generic versions of Adalat launch?

Adalat is a drug marketed by Bayer Pharms and Alvogen and is included in two NDAs.

The generic ingredient in ADALAT is nifedipine. There are thirty-nine drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

Summary for Tradename: ADALAT

Patents:0
Applicants:2
NDAs:2
Bulk Api Vendors: see list90
Clinical Trials: see list21
Patent Applications: see list9,033
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ADALAT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Pharms
ADALAT
nifedipine
CAPSULE;ORAL019478-001Nov 27, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-002Apr 21, 1993AB1RXYesYes► Subscribe► Subscribe► Subscribe
Bayer Pharms
ADALAT
nifedipine
CAPSULE;ORAL019478-002Sep 17, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-001Apr 21, 1993AB1RXYesNo► Subscribe► Subscribe► Subscribe
Alvogen
ADALAT CC
nifedipine
TABLET, EXTENDED RELEASE;ORAL020198-003Apr 21, 1993AB1RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ADALAT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Pharms
ADALAT
nifedipine
CAPSULE;ORAL019478-001Nov 27, 1985► Subscribe► Subscribe
Bayer Pharms
ADALAT
nifedipine
CAPSULE;ORAL019478-002Sep 17, 1986► Subscribe► Subscribe
Bayer Pharms
ADALAT
nifedipine
CAPSULE;ORAL019478-002Sep 17, 1986► Subscribe► Subscribe
Bayer Pharms
ADALAT
nifedipine
CAPSULE;ORAL019478-001Nov 27, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Colorcon
Novartis
Deloitte
Queensland Health
Harvard Business School
Express Scripts
Moodys
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot